Ventyx Biosciences (VTYX) 2024 Wells Fargo Healthcare Conference summary

Company overview and portfolio focus

• Bifunctional approach with IBD and NLRP3 portfolios, including S1P1 agonist and Crohn's disease molecule in phase II studies.

• Two NLRP3 compounds advancing: VTX2735 (peripheral) and VTX3232 (CNS-penetrant), both entering phase II trials.

• Evolution from immunology to immunology plus CNS immunology, targeting diseases with high unmet need.

• Emphasis on exploring neurodegenerative diseases and areas with previous clinical failures.

NLRP3 CNS-penetrant program (VTX3232)

• Developed using brain-penetrant scaffolds, achieving strong CNS and peripheral exposure.

• Phase I data show dose-dependent exposure in plasma and CSF, with near-equivalent partitioning.

• 10-15 mg QD can fully suppress IL-1 beta in CSF, the key NLRP3 target.

• Good safety profile and flexible dosing for upcoming phase II-A trials.

Obesity and cardiometabolic focus

• NLRP3 inhibition in animal models yields ~8-9% weight loss, not matching semaglutide but showing additive benefits.

• Animal data show improved lipid profiles, liver fat, renal biomarkers, and preservation of lean mass.

• Human trials will target obese patients with evidence of inflammation (e.g., high CRP) for likely benefit.

• Phase II-A trial to assess monotherapy and combination with incretins, focusing on broad metabolic endpoints.

• 12-week trial design chosen for robust efficacy and safety readouts, with biomarker and imaging endpoints.